Tomohide Yamada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/499456/publications.pdf

Version: 2024-02-01

933447 794594 21 642 10 19 citations h-index g-index papers 22 22 22 1298 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Frequentist performances of Bayesian prediction intervals for randomâ€effects metaâ€analysis. Biometrical Journal, 2021, 63, 394-405.	1.0	5
2	<i>>FTO</i> Obesity Variant–Exercise Interaction on Changes in Body Weight and BMI: The Taiwan Biobank Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3673-e3681.	3.6	4
3	Influence diagnostics and outlier detection for metaâ€analysis of diagnostic test accuracy. Research Synthesis Methods, 2020, 11, 237-247.	8.7	7
4	Myocardial infarction in type 2 diabetes using sodium–glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning. Current Medical Research and Opinion, 2020, 36, 403-409.	1.9	11
5	Understanding the experiences of long-term maintenance of self-worth in persons with type 2 diabetes in Japan: a qualitative study. BMJ Open, 2020, 10, e034758.	1.9	3
6	Deep Neural Network for Reducing the Screening Workload in Systematic Reviews for Clinical Guidelines: Algorithm Validation Study. Journal of Medical Internet Research, 2020, 22, e22422.	4.3	11
7	Slow Weight Loss During Comprehensive Treatment and Worse Metabolic Control with Higher Weight Regain: A Trajectory Analysis. Obesity, 2019, 27, 1925-1926.	3.0	O
8	Weekly Versus Daily Dipeptidyl Peptidase 4 Inhibitor Therapy for Type 2 Diabetes: Systematic Review and Meta-analysis. Diabetes Care, 2018, 41, e52-e55.	8.6	8
9	Sodiumâ€glucose coâ€transporterâ€2 inhibitors as addâ€on therapy to insulin for type 1 diabetes mellitus: Systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 1755-1761.	4.4	66
10	Biosimilar vs originator insulins: Systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2018, 20, 1787-1792.	4.4	21
11	Achieved glucose level and mortality risk in randomized clinical trials. Resuscitation, 2017, 110, e3-e4.	3.0	1
12	Glycemic control, mortality, secondary infection, and hypoglycemia in critically ill pediatric patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Medicine, 2017, 43, 1427-1429.	8.2	13
13	Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Medicine, 2017, 43, 1-15.	8.2	139
14	J-curve relation between daytime nap duration and type 2 diabetes or metabolic syndrome: A dose-response meta-analysis. Scientific Reports, 2016, 6, 38075.	3.3	49
15	Daytime Napping and the Risk of Cardiovascular Disease and All-Cause Mortality: A Prospective Study and Dose-Response Meta-Analysis. Sleep, 2015, 38, 1945-1953.	1.1	102
16	Successfully achieving target weight loss influences subsequent maintenance of lower weight and dropout from treatment. Obesity, 2015, 23, 183-191.	3.0	9
17	Linagliptin for elderly patients with type 2 diabetes. Lancet, The, 2014, 383, 306.	13.7	O
18	Male pattern baldness and its association with coronary heart disease: a meta-analysis. BMJ Open, 2013, 3, e002537.	1.9	25

TOMOHIDE YAMADA

#	Article	IF	CITATIONS
19	Chewing Betel Quid and the Risk of Metabolic Disease, Cardiovascular Disease, and All-Cause Mortality: A Meta-Analysis. PLoS ONE, 2013, 8, e70679.	2.5	53
20	Association of Adenovirus 36 Infection with Obesity and Metabolic Markers in Humans: A Meta-Analysis of Observational Studies. PLoS ONE, 2012, 7, e42031.	2.5	53
21	Erectile Dysfunction and Cardiovascular Events in Diabetic Men: A Meta-analysis of Observational Studies. PLoS ONE, 2012, 7, e43673.	2.5	62